A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples.
1/5 보강
[OBJECTIVES] We present Pancreas Genome Phenome Atlas (PGPA) as a resource for the mining and analysis of pancreatic -omics datasets, and demonstrate the biological interpretations possible due to thi
- 표본수 (n) 7760
APA
Oscanoa J, Ross-Adams H, et al. (2025). A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples.. Translational oncology, 62, 102550. https://doi.org/10.1016/j.tranon.2025.102550
MLA
Oscanoa J, et al.. "A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples.." Translational oncology, vol. 62, 2025, pp. 102550.
PMID
41045640
Abstract
[OBJECTIVES] We present Pancreas Genome Phenome Atlas (PGPA) as a resource for the mining and analysis of pancreatic -omics datasets, and demonstrate the biological interpretations possible due to this dynamic analytics hub accommodating an extensive range of publicly available datasets.
[METHODS] Clinical and molecular datasets from four primary sources are included (The Cancer Genome Atlas, International Cancer Genome Consortium, Cancer Cell Line Encyclopaedia, Genomics Evidence Neoplasia Information Exchange), which form the foundation of -omics profiling of pancreatic malignancies and related lesions (n = 7760 specimens). Several user-friendly analytical tools to integrate and explore molecular data derived from these primary specimens and cell lines are available. Crucially, PGPA is positioned as the data access point for Pancreatic Cancer Research Fund Tissue Bank - the only national pancreatic cancer biobank in the UK. This will pioneer a new era of biobanking to promote collaborative studies and effective sharing of multi-modal molecular, histopathology and imaging data (>125 000 specimens from >3980 cases and controls; >2700 radiology images, and >2630 digitised H&Es from 401 donors) to accelerate validation of in silico findings in patient-derived material.
[RESULTS] We demonstrate the practical utility of PGPA by investigating somatic variants associated with established transcriptomic subtypes and disease prognosis: several patient-specific variants are clinically actionable and may be leveraged for precision medicine.
[CONCLUSIONS] This places PGPA at the analytical forefront of pancreatic biomarker-based research, providing the user community with a distinct resource to facilitate hypothesis-testing on public data, validate novel research findings, and access curated, high-quality patient tissues for translational research.
[METHODS] Clinical and molecular datasets from four primary sources are included (The Cancer Genome Atlas, International Cancer Genome Consortium, Cancer Cell Line Encyclopaedia, Genomics Evidence Neoplasia Information Exchange), which form the foundation of -omics profiling of pancreatic malignancies and related lesions (n = 7760 specimens). Several user-friendly analytical tools to integrate and explore molecular data derived from these primary specimens and cell lines are available. Crucially, PGPA is positioned as the data access point for Pancreatic Cancer Research Fund Tissue Bank - the only national pancreatic cancer biobank in the UK. This will pioneer a new era of biobanking to promote collaborative studies and effective sharing of multi-modal molecular, histopathology and imaging data (>125 000 specimens from >3980 cases and controls; >2700 radiology images, and >2630 digitised H&Es from 401 donors) to accelerate validation of in silico findings in patient-derived material.
[RESULTS] We demonstrate the practical utility of PGPA by investigating somatic variants associated with established transcriptomic subtypes and disease prognosis: several patient-specific variants are clinically actionable and may be leveraged for precision medicine.
[CONCLUSIONS] This places PGPA at the analytical forefront of pancreatic biomarker-based research, providing the user community with a distinct resource to facilitate hypothesis-testing on public data, validate novel research findings, and access curated, high-quality patient tissues for translational research.